Evaluation of the Anti-Tumor Activity of Niclosamide Nanoliposomes Against Colon Carcinoma.

Abstract

BACKGROUND AND AIMS:

Niclosamide is an established anti-helminthic drug, which has recently been shown to inhibit the growth of various cancer cells. To exploit the potential anti-tumor activity of this drug for systemic use, the problem of low aqueous solubility should be addressed. The present study tested the in vivo anti-tumor effects of a recently developed nanoliposomal preparation of niclosamide in an experimental model of colon carcinoma.

METHODS:

The cytotoxicity of nanoliposomal niclosamide on CT26 colon carcinoma cells was evaluated using the MTT test. Inhibition of tumor growth was investigated in BALB/c mice bearing CT26 colon carcinoma cells. The animals were randomly divided into 4 groups including: 1) untreated control, 2) liposomal doxorubicin (15 mg/kg; single intravenous dose), 3) liposomal niclosamide (1 mg/kg/twice a week; intravenously for 4 weeks), and 4) free niclosamide (1 mg/kg/twice a week; intravenously for 4 weeks). To study therapeutic efficacy, tumor size and survival were monitored in 2-day intervals for 40 days.

RESULTS:

In vitro results indicated that nanoliposomal and free niclosamide could exert cytotoxic effects with IC50 values of 4.5 and 2.5 μM, respectively. According to in vivo studies, nanoliposomal niclosamide showed a higher growth inhibitory activity against CT26 colon carcinoma cells compared with free niclosamide as revealed by delayed tumor growth and prolongation of survival.

CONCLUSION:

Nnaoliposomal encapsulation enhanced anti-tumor properties of niclosamide in an experimental model of colon carcinoma.

• Authors: Mahdi Hatamipour, Mahmoud R Jaafari, Amir A Momtazi-Borojeni, Mahin Ramezani, Amirhossein Sahebkar
• Journal: Current molecular pharmacology (Curr Mol Pharmacol) Vol. 13 Issue 3 Pg. 245-250 ( 2020) ISSN: 1874-4702 [Electronic] United Arab Emirates
• PMID: 31433764 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright© Bentham Science Publishers; For any queries, please email at [email protected].

Chemical References

• Antineoplastic Agents
• Drug Carriers
• Liposomes
• Nanocapsules
• liposomal doxorubicin
• Polyethylene Glycols
• Doxorubicin
• Niclosamide

Topics

• Adenocarcinoma (drug therapy, pathology)
• Animals
• Antineoplastic Agents (administration & dosage, therapeutic use)
• Cell Line, Tumor
• Colonic Neoplasms (drug therapy, pathology)
• Doxorubicin (administration & dosage, analogs & derivatives, therapeutic use)
• Drug Carriers (administration & dosage)
• Drug Screening Assays, Antitumor
• Inhibitory Concentration 50
• Liposomes (administration & dosage)
• Male
• Mice
• Mice, Inbred BALB C
• Nanocapsules (administration & dosage)
• Niclosamide (administration & dosage, therapeutic use)
• Polyethylene Glycols (administration & dosage, therapeutic use)
• Random Allocation
• Solubility